Zolomide Capsule 250 mg is a chemotherapy drug used for treating a type of brain tumor (glioblastoma) which is normally fatal.
Zolomide Capsule 250 mg is mainly used to treat glioblastoma, a type of brain tumor, which is otherwise usually fatal. It is also used to treat advanced melanoma, a type of skin cancer.
Zolomide Capsule 250 mg works by inhibiting the enzymes that repair DNA damage. This makes cells more vulnerable to the effects of chemotherapy as they can no longer repair themselves. It also increases sensitivity to radiation therapy. By stopping the cells from repairing themselves, the body is able to break down the cancerous cells.
It typically takes between four and six weeks for Zolomide Capsule 250 mg to start working. During this time the patient will receive regular scans to monitor progress.
Zolomide Capsule 250 mg is rapidly and completely absorbed following oral administration. It is absorbed via the small intestine, with peak concentration occurring around three hours after ingestion.
Zolomide Capsule 250 mg is eliminated from the body primarily via the liver and excreted in the urine.
The standard dose for Zolomide Capsule 250 mg is 200 mg/m2/day. This dose is usually taken orally for five consecutive days, followed by a 23-day break. The dose may be adjusted depending on the patient's individual tolerance. The maximum recommended dose is 200 mg/m2/day.
Zolomide Capsule 250 mg is usually taken orally, either as a capsule or as a liquid suspension. It is usually taken with food to help reduce nausea and other side effects.
Common side effects of Zolomide Capsule 250 mg include nausea, vomiting, fatigue, loss of appetite, constipation, diarrhea, hair loss, skin changes, headache, dizziness, and confusion.
Zolomide Capsule 250 mg has been associated with a range of toxicities including myelosuppression, which is a reduction in the number of circulating blood cells, and neurotoxicity, which can affect the peripheral and central nervous system.
Zolomide Capsule 250 mg should be used with caution in patients with pre-existing hematological abnormalities, cardiac abnormalities, or hepatic or renal impairment. It is also important to monitor for signs of toxicity, including changes in blood cell counts, during treatment.
Certain drugs can interact with Zolomide Capsule 250 mg and increase the risk of toxicity. These include certain antibiotics, anticonvulsants, corticosteroids, and chemotherapeutic agents.
Zolomide Capsule 250 mg should be used with caution in the presence of certain diseases and conditions. These include hepatic or renal impairment, bone marrow suppression, and cardiac arrhythmias.
Certain drugs can interact with Zolomide Capsule 250 mg and increase the risk of toxicity. These include certain antibiotics, anticonvulsants, corticosteroids, and chemotherapeutic agents.
Food does not interact with Zolomide Capsule 250 mg, however it is important to take the medication with food so as to reduce the risk of nausea and vomiting.
Zolomide Capsule 250 mg is not recommended for pregnant women as it may harm the unborn baby. Women who are pregnant or plan to become pregnant should tell their doctor before taking Zolomide Capsule 250 mg.
It is not known if Zolomide Capsule 250 mg passes into breast milk or if it could harm a nursing infant. Women who are breast-feeding should tell their doctor before taking Zolomide Capsule 250 mg.
Symptoms of an acute overdose of Zolomide Capsule 250 mg may include drowsiness, confusion, nausea, vomiting, and seizures. Treatment of an overdose of this medication is symptomatic and supportive and should be done in a hospital setting.
Zolomide Capsule 250 mg is contraindicated in patients with hypersensitivity to it, other alkylating agents, or any other components of the product.
Zolomide Capsule 250 mg should be taken exactly as prescribed by the doctor. The capsules should be swallowed whole, not crushed, chewed, or opened. It is important that the patient adheres to the prescribed dose and schedule.
Zolomide Capsule 250 mg should be stored in a dry place at room temperature. It should not be frozen and should be kept away from light. It should be kept away from children.
The volume of distribution of Zolomide Capsule 250 mg is approximately 3.2 L/kg.
The half-life of Zolomide Capsule 250 mg is approximately 3-7 hours.
The clearance of Zolomide Capsule 250 mg is approximately 0.17 L/h/kg.
See in details version Zolomide Capsule 250 mg also Zolomide Capsule 250 mg in bangla